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Towards photon radiotherapy 
treatment planning with high Z nanoparticle 
radiosensitisation agents: the Relative Biological 
Effective Dose (RBED) framework
Jeremy M. C. Brown1,2,3*, Gerard G. Hanna4, Nathanael Lampe5, Balder Villagomez‑Bernabe1, James R. Nicol6, 
Jonathan A. Coulter6 and Fred J. Currell1
Introduction
Photon radiotherapy is one of the most commonly employed approaches in the treat-
ment of cancer (Delaney et al. 2005; Urruticoechea et al. 2010). Since its first applica-
tion in the 1920s, photon radiotherapy has undergone continuous refinement through 
the development of new technologies and increased understanding of radiation biology 
(Mayles et al. 2007; Joiner and van der Kogel 2009). Further optimisation has included 
the combination of radiotherapy and systemic therapy with resultant improvements in 
both local control and overall survival (Aupérin et al. 2010). Over the last decade, there 
has been increasing interest in the use of nanomedicines both as single-agent anti-can-
cer therapeutics and in combination with radiotherapy (Chen et  al. 2016; Schuemann 
et al. 2016; Marples and Dhar 2017). A novel class of nanomedicines, high Z nanopar-
ticle (NP) radiosensitisation agents, that possess the potential to further increase the 
efficacy of photon radiotherapy have recently entered the first phase of clinical trials 
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(National Institutes of Health (USA) 2016). These nanomedicines can be functionalised 
to seek out cancerous cells/tumours and when irradiated increase the local energy depo-
sition and free-radical yield within a few tens to hundreds of nanometres surrounding 
each NP (Hainfeld et al. 2004, 2008; Jones et al. 2010; McMahon et al. 2011; Jain et al. 
2012; Lechtman et al. 2013; Lin et al. 2014; Sicard-Roselli et al. 2014; Tran et al. 2016). 
However, the majority of in-vitro studies exploring the use of these nanomedicines for 
photon radiotherapy applications illustrate that the biological response of high Z NP-
doped cells do not directly scale with these factors alone (McMahon et al. 2011; Lecht-
man et al. 2013; Chithrani et al. 2010; Liu et al. 2010; Jain et al. 2011; Sancey et al. 2014; 
Nicol 2016).
The complex nature of biological response of high Z NP-doped cells under irradia-
tion from clinical photon radiotherapy sources presents a significant challenge when 
developing accurate treatment planning schemes. Initially, investigators attempted to 
apply a variety of Dose Enhancement Figures of Merit (DEFM) to evaluate the possible 
potential of high Z NP enhancement photon radiotherapy in the clinical setting (Cho 
2005; Roeske et al. 2007; Ngwa et al. 2010). These DEFMs were based on the assumption 
that the expected biological outcome of cells/tumours could be described via the ratio of 
dose deposition with and without high Z NP doping under uniform photon irradiation, 
a concept now known to possess limited validity (McMahon et al. 2011; Lechtman et al. 
2013; Chithrani et al. 2010; Liu et al. 2010; Jain et al. 2011; Sancey et al. 2014). For a high 
Z NP-enhanced photon radiotherapy treatment planning framework to be applicable to 
the clinical setting, it would need to account for the complex biological behaviour of NP-
doped cells whilst conveying the improved outcome in terms comparable with conven-
tional photon radiotherapy.
Recently Ferrero et al. (2017) and Strigari et al. (2017) presented a two article series 
on the treatment planning of radiotherapy for breast cancer using gold nanoparticles 
(AuNP). The first of these papers focused on the reformulation of the local effect model 
(LEM) to estimate AuNP-driven increase in radiosensitivity. Here a physics-driven addi-
tive approach was implemented based on the average number of ionisations per AuNP 
per Gy of dose, and the average number of AuNPs located inside or adjacent to the cell 
nucleus (Ferrero et  al. 2017). In the second paper, this formalism was applied to the 
treatment planning of breast cancer radiotherapy with 2-nm-diameter AuNPs utilising 
Eclipse v.8.9 (Varian Medical Systems, Palo Alto, CA, USA) (Strigari et al. 2017). From 
these works, it was illustrated that an improved treatment efficacy outcome is possi-
ble based on the developed formalism and selected targeting proprieties of the AuNPs. 
However, as highlighted in Ferrero et  al. this physics-driven approach neglects two 
major sets of physiological factors that underpin the biological response of NP-doped 
cells under irradiation: variation and localisation of AuNP uptake within/surrounding 
cells, and impact of AuNPs on toxicity and cellular cycle/repair processes (Ferrero et al. 
2017).
This work proposes a biological data-driven framework, the Relative Biological Effec-
tive Dose (RBED), that aims to enable pre-clinical and clinical treatment planning of 
high Z NP-enhanced photon radiotherapy. It combines the Relative Biological Effective-
ness (RBE) phenomenological model for proton radiotherapy outlined in Wilkens and 
Oelfke (2004), with the experimentally benchmarked NP radiosensitisation interpolation 
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framework of Brown and Currell (2017) to convey the observed increased biological 
effect in terms of conventional photon radiotherapy dose. The framework of Brown and 
Currell was developed to leverage available photon-NP biological radiosensitisation data 
to predict biological response with the specific purpose of accounting for the physiologi-
cal effects associated with variation and localisation of AuNP uptake within/surround-
ing cells, and impact of NPs on toxicity and cellular cycle/repair processes. To illustrate 
the viability of the RBED framework as a pre-clinical/clinical treatment planning tool, 
an in-silico study of neoadjuvant (preoperative) high Z NP-enhanced breast cancer MV 
photon radiotherapy was undertaken utilising the Monte Carlo radiation transport mod-
elling toolkit Geant4 (Agostinelli 2003; Allison 2006, 2016).
Method and materials
Relative Biological Effective Dose (RBED) framework
The RBED framework was developed to leverage available photon-NP biological radio-
sensitisation data to convey the increased biological response of high Z NP-enhanced 
photon radiotherapy on equal terms with conventional photon radiotherapy. In this 
work, two biological systems composed of the same cell line/tissue type are considered, 
one doped with a known concentration of a high Z NP radiosensitising agent (System A) 
and one without (System B). The survival fraction of these two systems after irradiation, 
SFA for System A and SFB for System B, can be described:
where DA and DB are the administered radiation doses, and αA , αB , βA and βB are the fit-
ted Linear Quadratic (LQ) model (Douglas and Fowler 1976) parameters of each respec-
tive system. These systems can be said to have biological equivalence when the survival 
fraction of their irradiated cell populations are equal:
which, after further manipulation, yields
Therefore, the RBED of the system containing the high Z NPs can be given via the posi-
tive solution for DB of this quadratic expression:
which is equivalent to Equation 3 in Wilkens and Oelfke (2004).
The key factor that dictates the accuracy of the phenomenological approach outlined 
above are the sourced values of each systems α and β . Whilst it is possible to obtain 
(1)SFA = exp
(
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2
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these values from a number different of sources, e.g. clonogenic cell assays, clinical trials, 
computational radiobiology, the majority of these high Z NP radiosensitisation studies 
for given cell line/tissue type are typically limited to two measurements for each tested 
photon source: a control and a single doped concentration (CM) . To enable the applica-
tion of these datasets to a clinically relevant scenario, i.e. varied high Z NP concentra-
tions (C) in different tissue regions, interpolated values for αA and βA can be determined 
using the interpolation framework of Brown and Currell (2017), i.e.,
where �α = αB(CM)− αA and �β = βB(CM)− βA . Substitution of Eq. 6 into Eq. 5 gives 
the final form of the RBED framework:
In‑silico study of high Z NP‑enhanced breast cancer MV photon radiotherapy
An in-silico platform was developed to illustrate the potential of the RBED framework 
for the medical exemplar of neoadjuvant (preoperative) breast cancer MV photon radio-
therapy (Calitchi et al. 2001; Riet et al. 2017) using the Monte Carlo radiation transport 
modelling toolkit Geant4 version 10.02.p02. The implemented simulation platform was 
designed to emulate the administration of a single 2 Gy fraction as part of a 50 Gy radio-
therapy treatment plan across a two-compartment spherical tumour located in the left 
breast of an adult female. Two different treatment scenarios, conventional and high Z 
NP enhanced, were explored for a set of 1 Gy on-axis tumour-shaped projections with 
a 6 MV Varian Linac photon source. For the high Z NP-enhanced treatment scenario, 
it was assumed that a sufficient quantity of the popular commercial proprietary thiol-
capped high Z NP radiosensitisation agent Aurovist (Hainfeld et al. 2004; Jain et al. 2011, 
2012; Rahman et al. 2009; Bobyk et al. 2013; Al Zaki et al. 2014; Her et al. 2017), 1.9-nm-
diameter gold nanoparticles (AuNPs), was administered to the patient to yield a maxi-
mum concentration within the two-compartment tumour of 500 μg/ml.
Figure 1 presents a set of cross-sectional views of the simulated adult female phan-
tom. The simulated adult female phantom was composed of a soft tissue elliptical 
cylinder containing the C1 to C7 vertebra of the spine, sternum, the seven attached 
ribs, both lungs and solid skewed ellipsoid representing the heart. Two fused cylin-
der-ellipsoids representing the breasts were contoured onto the surface of the ellipti-
cal cylinder centred in front of the third rib. Each breast is rotated 20° way from the 
sternum to mimic their resting position for a patient lying on their back. Within the 
left breast, a two-compartment tumour of diameters 20 mm and 16 mm is located 
20 mm in front of the breast centre away from the torso. In the case of the high Z 
NP-enhanced simulated irradiation, a uniform AuNP concentration of 250 μg/ml 
and 500 μg/ml was implemented for the inner and tumour wall regions, respectively, 
to approximate the uptake effects observed within solid tumours (Brown and Giac-
cia 1998; Minchinton and Tannock 2006; Hainfeld et al. 2011), whereas the remain-
ing soft tissue and organs was set to 25 μg/ml to emulate the small animal uptake 
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distributions for the Aurovist radiosensitisation agents observed in Hainfeld et  al. 
(2006, 2011). A summary of the material types of the different phantom components 
and their relative AuNP concentrations is outlined in Table 1. 
To achieve a minimum 2 Gy dose across the tumour and limit dose to non-tumour 
regions within the simulated phantom, the irradiation geometry, seen in Fig. 2 (left), 
was composed of a 30-mm-diameter circular non-diverging photon beam rotated 20° 
off-axis focused at the two-compartment tumour centre. Both treatment scenarios 
implemented two equal “exposure time” sub-fraction irradiations delivered in oppo-
site directions along the dashed axis seen in Fig.  2 (left). Each sub-fraction irradi-
ation simulated a total of 1.55× 1012 primary photons of energy sampled from the 
6 MV Varian Linac photon energy spectra presented in Fig. 2 (right). These simula-
tions were undertaken at the macroscopic scale with 1 mm3 Dose Volume Histogram 
(DVH) voxelisation using the Geant4 Option4 EM physics configuration. Atomic 
deexcitation, a maximum particle step length of 250  μm and a low-energy particle 
cutoff of 1 keV, was implemented to simulate the transport of primary photons and 
their generated secondary particles throughout the phantom.
The radiosensitisation response parameters, i.e. α and β values, for the AuNP-doped 
tissue types of the phantom were sourced from Jain et al. (2011). This study explored 
Fig. 1 Cross‑sectional view of the simulated adult female phantom at the centre of the first (top left), third 
(top right), fourth (bottom left) and sixth ribs (bottom right). In the top left and bottom right images, top 
and bottom cross sections of the lung volume can be seen, respectively. The top right cross section displays 
the central axis of the breasts and the two‑compartment tumour in addition to the lung walls, whereas 
the bottom left cross section displays the central axis of the solid skewed ellipsoid representing the heart 
in addition to the lung walls. A voxelised version of the phantom can be obtained at the Delft University of 
Technology Research Data repository (http://resea rchda ta.4tu.nl)
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the radiosensitisation of three different human cell lines, DU145 prostate cancer 
cells, MDA-MB-231 breast cancer cells and L132 lung epithelial cells, for the selected 
AuNP agent and discovered that only the AuNP-doped MDA-MB-231 breast cancer 
cells saw increased sensitisation at megavoltage energies (6 MV and 15 MV). Based 
on these findings, and the fact that the expected AuNP uptake in health tissue is sig-
nificantly lower than the tumour due to enhanced permeability and retention effects 
(Maeda 2012), it was assumed that only breast cells undergo an increased radiosen-
sitisation with the selected AuNP agent at megavoltage photon energies. Therefore 
Table 1 Material type and ratio of AuNP uptake of each phantom component seen in Fig. 1
A voxelised version of the phantom can be obtained at the Delft University of Technology Research Data repository (http://
resea rchda ta.4tu.nl)
Phantom component Material AuNP 
uptake 
(μg/
ml)
Ribs ICRU‑49 Compact Bone International Commission on Radiation Units and 
Measurements (1994)
0
Spine ICRU‑49 Compact Bone International Commission on Radiation Units and 
Measurements (1994)
0
Sternum ICRU‑49 Compact Bone International Commission on Radiation Units and 
Measurements (1994)
0
Heart ICRU‑44 Muscle International Commission on Radiation Units and Measure‑
ments (1989)
25
Lung wall ICRU‑44 Lung Tissue International Commission on Radiation Units and 
Measurements (1989)
25
Torso bulk ICRU‑44 Soft Tissue International Commission on Radiation Units and Meas‑
urements (1989)
25
Breast ICRU‑44 Breast Tissue International Commission on Radiation Units and 
Measurements (1989)
25
Tumour inner ICRU‑44 Breast Tissue International Commission on Radiation Units and 
Measurements (1989)
250
Tumour wall ICRU‑44 Breast Tissue International Commission on Radiation Units and 
Measurements (1989)
500
Fig. 2 Cross‑section of the simulated adult female phantom irradiation geometry (left) and primary photon 
energy spectra of the simulated 6 MV Varian Linac source taken from Sheikh‑Bagheri and Rogers (2002) 
(right). The solid and dashed yellow lines represent the outer edges and central axis, respectively, of the 
30‑mm‑diameter circular non‑diverging photon beam rotated 20° off‑axis focused at the two‑compartment 
tumour centre located in the left breast
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the heart, lung and soft tissue regions within the phantom were modelled as having 
a zero increase in radiosensitisation, whereas the breast tissue that makes up both 
breast and the tumour regions were modelled using the 6MV Varian Linac-irradiated 
MDA-MB-231 breast cancer cell parameters contained in Table 1 of Jain et al. (2011). 
To reflect the inherent uncertainty in-vitro clonogenic assays experiments, and the 
fundamental difference between cell culture and tissue response under irradiation, 
three different scenarios of radiobiological response was explored: minimum, mean 
and maximum relative AuNP agent radiosensitisation (see Table 2 for their α and β 
parameter values).
Results
Dose deposition within the conventional and AuNP‑doped phantom
Figure 3 presents dose maps of the adult female phantom, both conventional and AuNP 
doped, and their parallel and perpendicular dose profiles with respect to the simulated 
central axis of the photon beam. Inspection of these dose maps and profiles illustrate 
that (1) in each treatment scenario the majority of the dose deposited within the phan-
tom was limited to the target region defined via the edges of the shaped photon field out-
line in Fig. 2, and (2) the dose deposition in both the conventional and AuNP doped are 
effectively identical resulting in the overlap of their respective parallel and perpendicular 
profiles. The accompanying parallel dose profiles further illustrate that, as intended, the 
dose delivered throughout the left breast along the central axis of irradiation exceeded 2 
Gy in both treatment scenarios, whereas the perpendicular dose profiles show the pres-
ence of a dose gradient across the central target region of the photon beam, ± 10 mm, 
from left to right that approaches 2 Gy at the tumour’s right edge. This gradient is the 
result of two primary physical factors: different extents of spectral hardening and inten-
sity variation of the beam incident on the tumour surface [due to varied path lengths 
of beam through the left breast (Metcalfe et  al. 1990)], and beam broadening due to 
photon scattering [illustrated via the Gaussian like roll-off after ± 15 mm (Ahnesjö and 
Aspradakis 1999)]. However, even with these factors the minimum dose administered to 
the whole tumour in both simulated treatment scenarios reached the desired target of 2 
Gy (see Fig. 4).
Quantification of the observed minimal difference in the dose deposited between 
the two treatment scenarios can be visualised via each simulated phantom’s DVH, 
and minimum, mean and maximum breast tissue and whole tumour/tumour region 
Table 2 Phantom breast tissue α and  β values for  the  minimum, mean and  maximum 
radiosensitisation response scenarios for  high Z NP-enhanced photon radiotherapy 
with 1.9 nm Aurovist AuNPs under 6 MV Linac irradiation
Data taken from Jain et al. (2011) MDA-MB-231 breast cancer cell response. Minimum case α and β determine by minimising 
AuNP-doped and maximising conventional cell response within experimental uncertainty. Maximum case α and β 
determine by maximising AuNP-doped and minimising conventional cell response within experimental uncertainty
Scenario α β α β
(0 μg/ml) (500 μg/ml)
Minimum 0.024 0.086 0.064 0.087
Mean 0.002 0.079 0.104 0.098
Maximum 0.000 0.072 0.144 0.109
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delivered doses seen in Fig. 4. Comparison of each phantom regions DVHs and mean 
dose illustrates that there is less than 1% difference between the two treatment sce-
narios (which is on the same order of magnitude as the statistical accuracy of the sim-
ulation). Furthermore, both sets of DVHs illustrate that near-zero dose is deposited 
outside of the left breast and target tumour region.
Fig. 3 Dose maps of the adult female phantom, conventional (top left) and AuNP doped (bottom left), 
and accompanying parallel (top right) and perpendicular (bottom right) dose profiles with respect to the 
simulated central axis of the photon beam
Fig. 4 Dose Volume Histograms (DVHs) (left), and minimum, mean and maximum dose (right), illustrated via 
increasing transparency, of the simulated conventional and AuNP‑doped adult female phantom breast tissue 
and whole tumour/tumour regions. The conventional (solid) and AuNP‑doped (dashed) DVH profiles for the 
breast tissue and tumour regions differ by less than 1% causing an overlap
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RBED within the conventional and AuNP‑doped phantom
Figure 5 presents the RBED maps of the irradiated adult female phantom for the conven-
tional, minimum, mean and maximum relative AuNP agent radiosensitisation scenarios. 
With increasing relative radiosensitisation, the inner and tumour wall regions display an 
increased biological effect with respect to conventional radiotherapy (as indicated via 
increased RBED). The accompanying parallel and perpendicular RBED profiles of these 
maps further convey the extent of these increases within the inner and tumour wall 
regions of up to 3.08 and 3.67 Gy for the maximum radiosensitisation scenario, respec-
tively. However, these RBED profiles also illustrate an increased biological effect in the 
left breast that scales proportionally with relative AuNP radiosensitisation. This observ-
able increase within the left breast, which was less than 10% for all three relative radio-
sensitisation scenarios, highlights the need for correct selection of the high Z NP agent 
Fig. 5 RBED maps of the irradiated adult female phantom for the conventional (top left), minimum (top 
right), mean (middle left) and maximum (middle right) relative AuNP agent radiosensitisation scenarios. 
Accompanying parallel and perpendicular RBED profiles with respect to the simulated central axis of the 
photon beam can be seen in the bottom left and right panels, respectively
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to ensure maximised uptake in the target irradiation volume whilst minimising uptake in 
the surrounding non-target tissue. Accounting for this effect is expected to be one of the 
most important considerations in high Z NP-enhanced photon radiotherapy treatment 
planning to ensure maximum tumour control probability whilst minimising normal tis-
sue complications.
The RBED Volume Histograms (RVHs), and minimum, mean and maximum breast 
tissue and whole tumour/tumour region RBEDs for the conventional, minimum, mean 
and maximum relative AuNP agent radiosensitisation scenarios can be seen in Fig.  6. 
The observed trends in the RBED maps and profiles of Fig. 5 correlate with the increased 
RBED per unit volume of the left breast and tumour regions displayed in the RVHs. The 
extent of increase in mean RBED from the conventional to maximum relative AuNP 
agent radiosensitisation for the left and right breasts spans from 0.354 to 0.390 Gy and 
0.002 to 0.012 Gy, respectively, whereas for the tumour inner, tumour wall and whole 
tumour the mean RBED increases from 2.258 to 2.945 Gy, 2.241 to 3.478 Gy, and 2.250 
to 3.190 Gy.
Discussion
A novel framework for pre-clinical and clinical treatment planning of high Z NP-
enhanced photon radiotherapy was developed and its applicability tested in silico for the 
medical exemplar of neoadjuvant (preoperative) cancer MV photon radiotherapy. The 
Fig. 6 RBED Volume Histograms (RVHs) of the conventional and minimum (top left), mean (top right) and 
maximum (bottom left) relative AuNP agent radiosensitisation scenarios. Supporting minimum, mean and 
maximum RBED, illustrated via increasing transparency, of the simulated conventional, minimum, mean and 
maximum relative AuNP agent radiosensitisation adult female phantom breast tissue and whole tumour/
tumour regions can be found in the bottom right panel
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simulations undertaken with the developed in-silico platform illustrated that for a semi-
realistic uptake distribution of the selected AuNP radiosensitisation agent there was less 
than a 1% difference in the dose deposition throughout the standard and AuNP-doped 
adult female phantom. Application of the RBED framework for the three different rela-
tive AuNP agent radiosensitisation scenarios highlight that, even for this near-zero dose 
deposition difference, in every case an increase biological response was present in the 
left breast, right breast and tumour with respect to conventional radiotherapy. In fact, 
to achieve the same level of biological response within the tumour as the minimum, 
mean and maximum radiosensitisation scenarios, the conventional radiotherapy treat-
ment approach would require a 9%, 33% and 53% increase in radiation exposure, respec-
tively. Overall these results further illustrate the need of a framework such as RBED 
which is capable of accounting for the complex biological behaviour of NP-doped cells 
whilst conveying the improved outcome in terms comparable with conventional photon 
radiotherapy.
Whilst the findings of the present work point to the viability of the selected AuNP 
radiosensitisation agent for MV photon radiotherapy treatment of neoadjuvant breast 
cancer, due to a number of approximations it is difficult to draw a definite conclusion. 
Within the simulated adult female phantom, the distribution of the high Z NP radiosen-
sitisation agent uptake was simplified to a generic geometry due to the lack of supporting 
patient data. In reality, it is expected that the distribution of the high Z NP agent uptake 
within the patent will differ throughout various tissue regions and the target tumour due 
to its complex vascular structure (Brown and Giaccia 1998; Minchinton and Tannock 
2006). Moreover, the limited nature of available photon-NP biological radiosensitisation 
data forced a number of assumptions to be employed for the soft tissue response of the 
selected high Z NP agent under MV photon irradiation. If further supporting photon-
NP biological radiosensitisation data and anatomical uptake distributions within realis-
tic patient geometries could be obtained, it would be possible via the RBED framework 
to make an informed conclusion. However, the aim of this work was to introduce the 
RBED framework to the scientific community and illustrate that, with appropriate sup-
porting data, questions such as these could be explored via both in-silico and experi-
mental trials.
Conclusion
A novel framework for the pre-clinical and clinical treatment planning of high Z NP-
enhanced photon radiotherapy was developed and its applicability tested in silico for the 
medical exemplar of neoadjuvant (preoperative) breast cancer MV photon radiotherapy. 
Whilst a definite conclusion about the viability of the selected high Z NP  radiosen-
sitisation agents for the selected photon radiotherapy medical exemplar could not be 
obtained, it was illustrated with the RBED framework that the extent of possible biologi-
cal response was great than expected via the dose deposition alone. Further exploration 
of the role of high Z NP radiosensitisation agents in photon radiotherapy is warranted 
and it is anticipated that this framework will assist the scientific community in future 
high Z NP-enhanced in-silico, pre-clinical and clinical trials.
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